Aducanumab: A Deep Dive into BIIB037 and its Impact The medication, previously known as BIIB037, is a significant effort to treat early-stage Alzheimer's condition. Designed by Biogen, this molecule acts by removing https://www.targetmol.com/compound/aducanumab